A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC
Abstract Panobinostat (pano) is an FDA-approved histone deacetylase inhibitor. There is interest in evaluating alternate dosing schedules and novel combinations of pano for the treatment of upper aerodigestive and lung malignancies; thus we evaluated it in combination with Taxol, a chemotherapeutic...
Enregistré dans:
Auteurs principaux: | , , , |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2017
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/8bf6e32804f94f5480e8b18e2a01b3ef |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|